This table lists all the major pharma collaborations, acquisitions and mergers agreed during July 2013.
For an indepth analysis of these deals, read ‘Pharma deals during July 2013’
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Elan / Perrigo | Acquisition | Tysabri royalty stream, R&D programmes/ EU HQ & operations | 8,600 |
| Trius Therapeutics / Cubist Pharmaceuticals | Acquisition | Antibiotic pipeline inc TR-701 (tedizolid phosphate, p3) | 818 |
| *FibroGen / AstraZeneca | Strategic collaboration | FG-4592, oral treatment for anaemia in renal disease (p2/3) | 815 |
| Optimer Pharmaceuticals / Cubist Pharmaceuticals | Acquisition | Antibiotic pipeline based on Dificid (fidaxomicin) for C.difficile (approved) | 801 |
| Bever Pharmaceutical / Pharmstandard | Acquisition | Singapore-based pharma business | 630 |
| Immunocore / GSK | Research collaboration and licence | ImmTacs discovery platform against multiple targets | 510 |
| Quest Diagnostics / Royalty Pharma | Purchase of royalty rights | Ibrutinib (Bruton’s tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3) | 485 |
| Array BioPharma / Loxo Oncology | Multi-year licence and collaboration | Drug candidate (preclinical)+ discovery of small molecule drugs for oncology targets | 434 |
| Array BioPharma / Celgene | Collaboration and option | Programme targeting novel inflammation pathway (preclinical) | 387 |
| Ceptaris Therapeutics / Actelion | Acquisition | Valchlor for mycosis fungoides-type CTCL (NDA) | 250 |
| Syntaxin / Ipsen | Acquisition of 90% stake | Serenbotase (p2) and other recombinant botulinum toxins | 210 |
| Medicago / Mitsubishi Tanabe Pharma | Acquisition of 60% stake | Portfolio of flu and other vaccines based on VLPs (p2) | 208 |
| Talon Therapeutics / Spectrum Pharmaceuticals | Acquisition | Haemato-oncology portfolio, Marqibo for leukaemia (FDA approved) | 206 + shares |
| Bionomics / Merck & Co | Option and licence | ionX drug discovery and MultiCore chemistry platform (discovery) | 172 |
| Nerviano Medical Sciences / Servier | Collaboration, licence, option | Protein kinase TTK/MPS1 inhibitors (preclinical) | 143 |
| Lilly / Transition Therapeutics | Licence, collaboration and option*‡ | TT-601 for osteoarthritis pain (preclinical) | 130*‡ |
| **Vivus / Berlin-Chemie (Menarini) | Licence, commercialisation, supply | Spedra (avanafil) for erectile dysfunction (approved) | 121 |
| ‡Optinose / Avanir Pharmaceuticals | Licence | Breath Powered intranasal sumatriptan for migraine (p3) | 110 |
| Acetylon Pharmaceuticals / Celgene | Collaboration and option to acquire | HDAC inhibitors inc ACY-1215 for multiple myeloma (p1b) | 100 |
| ‡‡Servier / Amgen | Cardiovascular collaboration, licence and option | Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2) | 50 |
| Opalia Pharma / Recordati | Acquisition of 90% stake | Branded generic drugs – dermatology, GI, respiratory | 49 |
| †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum | Development, supply and commercialisation | Xiapex (collagenase clostridium histolyticum) (approved) | 40 |
All deals are worldwide unless otherwise noted – see below:
* US, China and all major markets ex Japan, Europe, CIS, Middle East, South Africa
** Over 40 European countries, Australia, New Zealand
‡ North America
‡‡ Amgen receives US rights to Servier’s ivabradine and an exclusive option to Servier’s S-38844 in the US; Servier receives rights in Europe for omecamtiv mecarbil
† EU
*‡ Payable to Transition Therapeutics if Lilly exercises its option to re-acquire at clinical proof of concept
Abbreviations
ImmTacs = Immune mobilising mTCR against cancer
CLL = chronic lymphocytic leukaemia
CTCL = cutaneous T-cell lymphoma
VLP = virus-like particle produced in plant expression systems